Medical silicone pressure sensitive adhesive composition

Abstract

The present invention relates to a compound having at least two C groups per molecule, each bonded to a silicon atom. 2 ~C 6 A medical silicone pressure sensitive adhesive composition comprising at least one organopolysiloxane gum A containing alkenyl groups, at least one organopolysiloxane resin B containing one or more OH groups bonded to silicon atoms, at least one organopolysiloxane extender CE having exactly two terminal hydrogen atoms bonded to silicon atoms, optionally at least one organopolysiloxane crosslinker XL having at least three hydrogen atoms bonded to silicon atoms, at least one hydrosilylation catalyst D, at least one solvent E and optionally at least one hydrosilylation inhibitor F, wherein the organopolysiloxanes A, CE and XL have a molar ratio RHAlk of 2 to 5 and a ratio nH XL / nH CE is selected so that is less than 0.10.

Description

[Technical field]

[0001] The field of the invention is that of medical pressure sensitive adhesives (PSA). In particular, the invention relates to a medical silicone pressure sensitive adhesive composition, a method for coating a substrate with the medical silicone pressure sensitive adhesive composition, and a skin adhesive article obtainable by said method. [Background technology]

[0002] PSA is an abbreviation of the term "pressure-sensitive adhesive", which is well known in the art and is widely used in various applications, especially in medical applications. Currently, in the medical market, most of the skin contact products, such as tapes, patches and bandages, are prepared with acrylic PSA. However, acrylic PSA has some disadvantages, such as poor sweat resistance (water resistance), poor biocompatibility, and high sensitization rate to human skin, especially infants.

[0003] Silicone-based PSAs are also widely used in medical applications for use on or in contact with the skin. Silicone-based PSAs can adhere to surfaces by simple contact or under the influence of light pressure. It has great advantages over acrylic-based PSAs. Silicone-based PSAs exhibit advantageous properties for medical applications due to their breathability, water resistance, low irritation and biocompatibility. For example, silicone-based PSAs are suitable for the high requirements of novel medical applications due to their biocompatibility and permeability, allowing the diffusion of oxygen, carbon dioxide and water vapor, making them suitable for medical applications where ventilation is preferably required.

[0004] WO2017 / 158249Al and WO2017 / 051083 disclose skin-adhesive silicone gel. Silicone gel is useful for wound care applications because its inherent properties make it non-adhesive to wet skin, and therefore avoid secondary damage to wounds during the use of dressings.However, for non-traumatic medical materials attached to skin, moist environments or sweating often cause the gel to lose its adhesiveness and then peel off.

[0005] US2007 / 0202245A1 discloses a method for improving the adhesion of silicone gels to medical substrates by including hydroxy-substituted siloxane resins in the gel formulation. Nevertheless, the improved formulations disclosed in this document are still silicone gels.

[0006] WO2020 / 099999Al describes a medical silicone pressure-sensitive adhesive. The silicone composition is cured by a polycondensation reaction: a condensation product is formed by the reaction between a polyorganosiloxane containing terminal hydroxyl groups and a silicate resin, and then a non-reactive polyorganosiloxane is added. In the subsequent tape manufacturing process, an electron beam is used to promote crosslinking of the non-reactive polyorganosiloxane, thereby forming a layer of pressure-sensitive adhesive on the substrate. The manufacturing process of this PSA is complex, and control of the condensation reaction conditions has a significant impact on the quality of the product.

[0007] Thus, there is a continuing need to have silicone-based pressure-sensitive adhesive compositions that have excellent overall properties suitable for medical applications. Summary of the Invention

[0008] The present invention solves the problems of the prior art.

[0009] The present invention relates to a medical silicone pressure-sensitive adhesive composition, the medical silicone pressure-sensitive adhesive composition comprising: At least two C per molecule, each bonded to a silicon atom 2 ~C 6at least one organopolysiloxane A containing alkenyl groups, the organopolysiloxane A being an organopolysiloxane gum; at least one organopolysiloxane resin B containing one or more OH groups bonded to silicon atoms; at least one organopolysiloxane extender CE having exactly two terminal hydrogen atoms bonded to a silicon atom; Optionally, at least one organopolysiloxane crosslinker XL having at least three hydrogen atoms bonded to silicon atoms, at least one hydrosilylation catalyst D; At least one solvent E; Optionally, at least one hydrosilylation inhibitor F; Including, The organopolysiloxanes A, CE and XL have a molar ratio RHAlk=tH / tAlk of 2 to 5, and the ratio nH XL / nH CE is chosen to be less than 0.10, where tH=the number of moles of hydrogen atoms directly bonded to silicon atoms of the organopolysiloxanes CE and XL; tAlk=the number of moles of alkenyl bonded directly to silicon atoms of organopolysiloxane A; nH XL = the number of moles of hydrogen atoms directly bonded to silicon atoms of organopolysiloxane XL, nH CE = the number of moles of hydrogen atoms directly bonded to silicon atoms of the organopolysiloxane CE.

[0010] The medical silicone pressure sensitive adhesive composition according to the present invention is a precursor to the silicone pressure sensitive adhesive G and is crosslinkable by hydrosilylation.

[0011] The present invention further relates to a method for producing a skin adhesive article, comprising the steps of coating, continuously or discontinuously, at least one of the two sides of a substrate with the medical silicone pressure-sensitive adhesive composition defined above, and crosslinking said medical silicone pressure-sensitive adhesive composition to give silicone pressure-sensitive adhesive G.

[0012] Another object of the invention is a skin adhesive article comprising a substrate, at least one of the two faces of which is coated with a silicone pressure-sensitive adhesive G obtained by crosslinking the medical silicone pressure-sensitive adhesive composition defined above.

[0013] It has been found that medical silicone pressure-sensitive adhesives offering excellent properties suitable for medical applications can be obtained from silicone pressure-sensitive adhesive compositions as defined above which contain no or very small amounts of organopolysiloxane crosslinker XL when the molar ratio RHAlk is between 2 and 5.

[0014] Suitable properties for a medical silicone pressure sensitive adhesive are good overall properties such as ease of tearing, no visible residue on the skin, good anchoring to the substrate, good peel adhesion, good tack, adequate release force, and acceptable repositionability. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] All viscosities considered in this specification correspond to the magnitude of the "Newtonian" dynamic viscosity at 25°C, i.e. the dynamic viscosity measured in a manner known per se using a Brookfield viscometer at shear rate gradients sufficiently low that the measured viscosity is independent of the velocity gradient.

[0016] The consistency or penetrability of gums is typically determined at 25°C using a penetrometer of type PNR12 or equivalent model, which allows the application of a cylindrical head to the sample under standardized conditions. The penetrability of gums is the depth to which a calibrated cylinder penetrates into the sample in one minute, expressed in tenths of a millimeter. For example, the following method is given: A sample of gum is introduced into an aluminum container of 40 mm diameter and 60 mm height. The cylindrical head, made of bronze or brass, is 6.35 mm in diameter and 4.76 mm in height and is supported by a metal rod of 51 mm length and 3 mm diameter that fits the penetrometer. This rod is overloaded with 100 g. The total weight of the assembly is 151.8 g, including the 4.3 g cylindrical part and its supporting rod. The container containing the gum sample is placed in a thermostatically controlled bath at 25±0.5°C for at least 30 minutes. The measurements are carried out according to the manufacturer's instructions. The value of the depth (V) (in tenths of a millimeter) and the value of the time (t) to reach this depth (in seconds) are indicated on the device. The penetration is equal to 60V / t, expressed in tenths of a millimeter per minute.

[0017] Nomenclature known in the silicone art is used herein to describe polyorganosiloxanes, and the following letters are used to describe the siloxy units: M, D, T, and Q. The letter M represents a group of the formula (R 1 ) 3 SiO 1 / 2 The letter D represents a monofunctional unit (R 1 ) 2 SiO 2 / 2 where the silicon atom is bonded to two oxygen atoms. The letter T represents the formula (R 1 )SiO 3 / 2 The letter Q represents a trifunctional unit of the formula SiO 4 / 2 where the silicon atom is bonded to four oxygen atoms. 1represents a group. The M, D and T units can be functionalized. Reference is now made to the M, D and T units, identifying the particular groups.

[0018] Component A is at least two C 2 ~C 6 It may be an alkyl substituted silicone polymer.

[0019] Preferably, at least one organopolysiloxane A is (i) at least two siloxyl units of formula (A1): (Y) a (Z) b SiO (4+(a+b))) / 2 (A1) Where: Y represents a monovalent group containing 2 to 6 carbon atoms and having at least two alkenyl groups; Z represents a monovalent group containing 1 to 20 carbon atoms and not containing an alkenyl group, a and b represent integers, a is 1, 2 or 3, b is 0, 1 or 2, and (a+b) is 1, 2 or 3; and (ii) optionally other siloxyl units of formula (A2): (Z) c SiO (4-c) / 2 (A2) Where: Z has the same meaning as above, c represents an integer of 1, 2 or 3, may include.

[0020] According to the invention, in the definition of the organopolysiloxane in formula (A1), the symbol a can preferably be equal to 1 or 2, and even more preferably equal to 1. Furthermore, in formulas (A1) and (A2), the symbol Z can preferably be equal to an alkyl group containing 1 to 8 carbon atoms, which may be substituted with at least one halogen atom, and C 6 ~C 10Z may represent a monovalent radical selected from the group formed by aryl radicals. Z may advantageously represent a monovalent radical selected from the group formed by methyl, ethyl, propyl, 3,3,3-trifluoropropyl, xylyl, tolyl and phenyl. In addition, in formula (A1), the symbol Y may advantageously represent a radical selected from the group consisting of vinyl, propenyl, 3-butenyl and 5-hexenyl. Preferably, the symbol Y is vinyl and the symbol Z is methyl.

[0021] Organopolysiloxane gum A has a linear structure. It essentially consists of Formula(Y) 2 SiO 2 / 2 , (Y)(Z)SiO 2 / 2 and (Z) 2 SiO 2 / 2 and a siloxyl unit "D" selected from the units Formula(Y) 3 SiO 1 / 2 , (Y) 2 (Z)SiO 1 / 2 , (Y)(Z) 2 SiO 1 / 2 and (Z) 3 SiO 2 / 2 Siloxyl unit "M" selected from the units

[0033] where the symbols Y and Z are as defined above.

[0022] Preferably, the linear organopolysiloxane A has a degree of polymerization in the range of 2,000-10,000, more preferably 2,000-8,000, more preferably 2,000-5,000.

[0023] Examples of units "D" include dimethylsiloxy, methylphenylsiloxy, methylvinylsiloxy, methylbutenylsiloxy, methylhexenylsiloxy, methyldecenylsiloxy and methyldecadienylsiloxy groups.

[0024] Examples of the unit "M" include trimethylsiloxy, dimethylphenylsiloxy, dimethylvinylsiloxy, and dimethylhexenylsiloxy groups.

[0025] Organopolysiloxane A may preferably be a polymer having a weight average molecular weight Mw of 260,000 g / mol to 1,000,000 g / mol, preferably 400,000 g / mol to 1,000,000 g / mol, more preferably 400,000 g / mol to 900,000 g / mol.

[0026] Examples of useful organopolysiloxanes A are: Polydimethylsiloxanes containing dimethylvinylsilyl end groups, Poly(methylphenylsiloxane-co-dimethylsiloxane) containing dimethylvinylsilyl end groups, Poly(vinylmethylsiloxane-co-dimethylsiloxane) containing dimethylvinylsilyl end groups, Poly(dimethylsiloxane-co-vinylmethylsiloxane) containing trimethylsilyl end groups The following can be mentioned.

[0027] Particularly advantageously, the organopolysiloxane A is a polydimethylsiloxane containing dimethylvinylsilyl end groups and having a weight-average molecular weight Mw of 260,000 g / mol to 1,000,000 g / mol, preferably 400,000 g / mol to 900,000 g / mol. Particularly advantageous organopolysiloxanes A are of the formula M Vi D a M Vi where: M Vi = Formula: (vinyl)(CH 3 ) 2 SiO 1 / 2 is a siloxyl unit of ·D=Formula:(CH 3 ) 2 SiO 2 / 2 is a siloxyl unit of ·a is a number from 2000 to 6000, preferably from 3000 to 5500.

[0028] Organopolysiloxane A can be used in an amount of 15% to 45% by weight, preferably 20% to 40% by weight, based on the total amount of components A + B + XL + CE. According to one embodiment, Organopolysiloxane A has an alkenyl content of 0.001% to 0.5% by weight, preferably 0.005% to 0.025% by weight, more preferably 0.008% to 0.018% by weight, based on the total amount of Organopolysiloxane A.

[0029] Preferably, Organopolysiloxane A can be selected from polydimethylsiloxane with dimethylvinyl as the end group, polydimethylmethylvinylsiloxane with dimethylvinyl as the end group, and polydimethylmethylvinylsiloxane with trimethyl as the end group, and more preferably, it can be selected from polydimethylsiloxane with dimethylvinyl as the end group.

[0030] According to one embodiment, Organopolysiloxane A is an organopolysiloxane gum having a consistency at 25°C of 200 mm / 10 to 2000 mm / 10, preferably 300 mm / 10 to 1800 mm / 10, more preferably 500 mm / 10 to 1500 mm / 10.

[0031] According to one embodiment, Organopolysiloxane A is an organopolysiloxane gum having a weight average molecular weight Mw of 260,000 g / mol to 1,000,000 g / mol, preferably 400,000 g / mol to 1,000,000 g / mol, more preferably 400,000 g / mol to 900,000 g / mol. The weight average molecular weight Mw is determined by gel permeation chromatography using polystyrene as the standard.

[0032] According to one embodiment, Organopolysiloxane A is an organopolysiloxane gum having a viscosity higher than 600,000 mPa·s at 25°C, preferably higher than 1,000,000 at 25°C.

[0033] According to one embodiment, the medical silicone pressure sensitive adhesive composition according to the present invention further comprises at least one organopolysiloxane A″ which is an oil having a dynamic viscosity of 10 mPa·s to 500,000 mPa·s at 25° C., preferably 100 mPa·s to 100,000 mPa·s at 25° C., more preferably 10,000 mPa·s to 100,000 mPa·s at 25° C. The organopolysiloxane A″ may be linear or branched and may have an alkenyl content of 0.05% to 0.5% by weight relative to the total amount of component A″.

[0034] The organopolysiloxane B containing hydroxyl groups bonded to Si atoms can be selected from the usual organopolysiloxane resins, among which those having the formula (R 2 ) 3 SiCl, (R 2 ) 2 Si(Cl) 2 , R 2 Si(Cl) 3 and Si(Cl) 4 These resins are well-known branched organopolysiloxane oligomers or polymers and are commercially available. They have in their structure the formula (R 2 ) 3 SiO 1 / 2 (M units), (R 2 ) 2 SiO 2 / 2 (D unit), R 2 SiO 3 / 2 (T units) and SiO 4 / 2 (Q units), where at least one of these units is a T or Q unit. 2 The group is a resin having approximately 0.8 to 1.8 R 2 Furthermore, these resins are not fully condensed and contain OH groups. 2The groups may be the same or different, linear or branched C 1 ~C 6 Alkyl group, C 2 ~C 4 For example, an alkyl group R 2 The groups include methyl, ethyl, isopropyl, tert-butyl and n-hexyl groups, and the alkenyl groups include vinyl or allyl groups. 2 The group is a methyl or hydroxyl group.

[0035] According to a particular embodiment, the hydroxyl-containing organopolysiloxane resin B is a) The following formula: M=R 3 R 4 R 5 SiO 1 / 2 , and Q (OH) =(OH)SiO 3 / 2 M and Q (OH) Contains siloxy units, Optionally, siloxy units Q=SiO 4 / 2 is a copolymer in which MQ (OH) A type of hydroxylated silicone resin, b) the following formula: M=R 3 R 4 R 5 SiO 1 / 2 , D Vi =(Vi)(R 3 )SiO 2 / 2 and Q (OH) =(OH)SiO 3 / 2 M,D Vi and Q (OH) Contains siloxy units, Optionally, siloxy units Q=SiO 4 / 2 is a copolymer in which Vi Q (OH) A type of hydroxylated silicone resin, c) The formula: M=R 3 R 4 R 5 SiO 1 / 2 , M Vi =(Vi)(R 3 )(R 4 )SiO 2 / 2 and Q (OH) =(OH)SiO 3 / 2 M,M Vi and Q (OH) Contains siloxy units, Optionally, siloxy units Q=SiO 4 / 2 MM is a copolymer in which Vi Q (OH) A type of hydroxylated silicone resin, d) The following formula: M=R 3 R 4 R 5 SiO 1 / 2 , D=R 3 R 4 SiO 2 / 2 , T (OH) =(OH)R 3 SiO 2 / 2 , T=R 3 SiO 3 / 2 M, D, T (OH) and MDT, a copolymer containing T siloxy units. (OH) T-type hydroxylated silicone resins, as well as e) The formula: D=R 3 R 4 SiO 2 / 2 , T (OH) =(OH)R 3 SiO 2 / 2 , T=R 3 SiO 3 / 2 D, T (OH) and T siloxy units, DT (OH)T-type hydroxylated silicone resin is selected from the group consisting of where Vi is a vinyl group and R 3 , R 4 and R 5 But independently of each other, linear or branched alkyl groups having 1 to 8 carbon atoms and optionally substituted with one or more halogen atoms, preferably selected from the group consisting of methyl, ethyl, isopropyl, tert-butyl and n-hexyl groups, and an aryl or alkylaryl group having 6 to 14 carbon atoms and preferably selected from the group consisting of phenyl, xylyl and tolyl groups; is selected from.

[0036] According to a preferred embodiment, examples of organopolysiloxane resins B may include those selected from at least one of MQ resins, MDQ resins, DT resins and MDT resins, in which the OH groups can be carried by Q and / or T units.

[0037] According to another preferred embodiment, the organopolysiloxane resin B is MQ (OH) , MQQ (OH) Or M.M. Vi Q (OH) It is a hydroxylated silicone resin of the type, containing 0.1% to 4% by weight, preferably 0.3% to 2.0% by weight, more preferably 0.5% to 1.5% by weight of hydroxyl groups relative to the dry weight of organopolysiloxane resin B. Preferably, the ratio of M units to Q units is 0.5 to 1.2, preferably 0.6 to 0.9. Component B can have a weight average molecular weight Mw of 3000 g / mol to 12000 g / mol, preferably 4000 g / mol to 11000 g / mol.

[0038] In the composition of the present invention, organopolysiloxane resin B can be used as a tackifier.

[0039] The organopolysiloxane resin B can be used in an amount of 25% by weight to 80% by weight, preferably 40% by weight to 60% by weight, based on the total amount of components A+B+XL+CE.

[0040] Preferably, the weight ratio of component B to component A may be from 0.8 to 2.5, preferably from 1.0 to 2.0.

[0041] Component CE, also referred to as the "chain extender" or simply "extender", is an organopolysiloxane having exactly two terminal hydrogen atoms bonded to Si.

[0042] For example, the organopolysiloxane extender CE according to the present invention may be two siloxyl end units, which may be identical or different, of the formula (CE-1): (H)(R 6 ) 2 SiO 1 / 2 (CE-1) Where: Symbol R 6 is C 1 ~C 8 Alkyl group or C 6 ~C 10 corresponding to an aryl group, the symbol H represents a hydrogen atom; at least two siloxyl units of the formula (CE-2): (R 7 ) 2 SiO 2 / 2 (CE-2) Here, the group R 7 is C 1 ~C 8 Alkyl group or C 6 ~C 10 corresponding to the aryl group, may include With the proviso that the organopolysiloxane CE contains two hydrogen atoms per polymer, each hydrogen atom being bonded to a different silicon atom, and preferably the organopolysiloxane CE contains two siloxyl units of formula (CE-1) and at least one siloxyl unit of formula (CE-2) per polymer.

[0043] As examples of organopolysiloxanes CE, mention may be made of polydimethylsiloxanes containing dimethylhydrogensilyl end groups and having a dynamic viscosity at 25° C. of 1 mPa·s to 1000 mPa·s, preferably 5 mPa·s to 500 mPa·s, and even more preferably 5 mPa·s to 300 mPa·s. Particularly advantageous organopolysiloxanes CE are of the formula M H D X M H where: M H =Formula:(H)(CH 3 ) 2 SiO 1 / 2 is a siloxyl unit of ·D=Formula:(CH 3 ) 2 SiO 2 / 2 is a siloxyl unit of x is an integer of 1 to 200, preferably 1 to 150, and further more preferably 3 to 120.

[0044] Organopolysiloxanes CE are described as "chain extenders" because when SiH reactive functional groups are at the chain ends, they have the presumed effect of increasing the mesh size of the network during crosslinking.

[0045] Component CE can have a dynamic viscosity at 25° C. of 1 mPa·s to 1000 mPa·s, preferably 5 mPa·s to 500 mPa·s, and more preferably 5 mPa·s to 300 mPa·s.

[0046] Component CE may have a Si-H content of 0.2 wt % to 10 wt %, preferably 0.3 wt % to 8.0 wt %, and more preferably 0.4 wt % to 6.0 wt %, based on the total weight of component CE.

[0047] Preferably, the organopolysiloxane extender CE can be a dimethylhydrogen terminated polydimethylsiloxane.

[0048] The organopolysiloxane extender CE may be used in an amount of 5% to 20% by weight based on the total amount of components A+B+XL+CE.

[0049] As distinct from the chain extender CE, component XL, also called "crosslinker", is an organopolysiloxane having at least three hydrogen atoms bonded to Si. The organopolysiloxane crosslinker XL is an optional component of the composition according to the invention. If present, the organohydrogensiloxane crosslinker XL can be as disclosed below.

[0050] For example, the organohydrogensiloxane crosslinker XL according to the present invention is at least three siloxyl units of the formula (XL-1): (H)(L) e SiO (3-e) / 2 (XL-1) Here, the symbol H represents a hydrogen atom, and the symbol L represents an alkyl group having 1 to 8 carbon atoms or a C 6 ~C 10 aryl, where the symbol e is equal to 0, 1 or 2, and Optionally, other siloxyl units of formula (XL-2): (L) g SiO (4-g) / 2 (XL-2) where the symbol L is an alkyl group having 1 to 8 carbon atoms or 6 ~C 10 aryl, wherein the symbol g is equal to 0, 1, 2 or 3; may include However, there is a proviso that the organopolysiloxane XL contains 0.5% to 15.0% by weight of Si-H functional groups per polymer, preferably 1.0% to 12.5% ​​by weight of Si-H functional groups per polymer, and even more preferably 1.5% to 10.0% by weight of Si-H functional groups per polymer.

[0051] The organopolysiloxanes XL according to the present invention which have crosslinkable functional groups and are useful are represented by the formula M H D x D Hw M H , M H D x D H y M and MD x D H z M, in which: M H =Formula:(H)(CH 3 ) 2 SiO 1 / 2 is a siloxyl unit of D H =Formula:(H)(CH 3 )SiO 2 / 2 is a siloxyl unit of ·D=Formula:(CH 3 ) 2 SiO 2 / 2 is a siloxyl unit of ·M=formula(CH 3 ) 3 SiO 1 / 2 is a siloxyl unit of X is a number from 0 to 500, preferably from 2 to 250, and further more preferably from 5 to 80; w is a number from 1 to 500, preferably from 1 to 250 or 1 to 100, and further more preferably from 1 to 70; y is a number from 2 to 500, preferably from 3 to 250 or from 2 to 100, and further more preferably from 2 to 70; z is a number from 3 to 500, preferably from 3 to 250 or 3 to 100, and further more preferably from 3 to 70; The polymer contains from 0.5% to 15.0% by weight of Si-H functional groups per polymer, preferably from 1.0% to 12.5% ​​by weight of Si-H functional groups per polymer, and even more preferably from 1.5% to 10.0% by weight of Si-H functional groups per polymer.

[0052] Component XL can have a dynamic viscosity of 40 mPa·s to 1000 mPa·s at 25° C., preferably 50 mPa·s to 750 mPa·s at 25° C., and more preferably 60 mPa·s to 500 mPa·s at 25° C. If the viscosity of Component XL is less than 40 mPa·s at 25° C., the cured PSA will have too much cohesion to peel off easily, and strong cohesion will result in poor adhesion to the substrate, leaving a residue of bits on the skin when the cured PSA layer is peeled off.

[0053] Component XL may have a Si-H content of 0.5 wt % to 15 wt %, preferably 1.0 wt % to 12.5 wt %, and more preferably 1.5 wt % to 10.0 wt %, based on the total weight of component XL.

[0054] Preferably, the organopolysiloxane crosslinker XL can be a trimethylsiloxy-terminated polymethylhydrogensiloxane or a dimethylhydrogen-terminated polymethylhydrogensiloxane.

[0055] The content of organopolysiloxanes A, CE and XL in the composition according to the invention is determined in two molar ratios: ·Ratio RHAlk=tH / tAlk ·ratio nH XL / nH CE Selected by Where: tH = the number of moles of hydrogen atoms directly bonded to silicon atoms of the organopolysiloxanes CE and XL, tAlk=the number of moles of alkenyl directly bonded to silicon atoms of organopolysiloxane A, nH XL = the number of moles of hydrogen atoms directly bonded to silicon atoms of organopolysiloxane XL, nH CE = the number of moles of hydrogen atoms directly bonded to silicon atoms of the organopolysiloxane CE.

[0056] According to the present invention, the molar ratio RHAlk is 2 to 5, preferably 2.5 to 4. According to the present invention, the ratio nH XL / nH CE is less than 0.10, preferably from 0 to 0.08, more preferably from 0 to 0.05. According to a preferred embodiment, the composition according to the present invention is free or substantially free of organohydrogensiloxane crosslinker XL.

[0057] Useful hydrosilylation catalysts D according to the invention include compounds of metals belonging to the platinum group, well known to those skilled in the art. The platinum group metals are known as platinoids, a name grouping together platinum, ruthenium, rhodium, palladium, osmium and iridium. It is preferable to use compounds of platinum and rhodium. In particular, the complexes of platinum and organic products described in patents US 3,159,601, US 3,159,602 and US 3,220,972 and European patents EP 0057459, EP 0188978 and EP 0190530, as well as the complexes of platinum and vinylorganosiloxanes described in patent US 3,419,593, can be used. The generally preferred catalyst is platinum. Examples include, inter alia, black platinum, chloroplatinic acid, chloroplatinic acid modified with alcohols, and complexes of chloroplatinic acid with olefins, aldehydes, vinylsiloxanes or acetylenic alcohols. Karstedt solutions or complexes, chloroplatinic acid hexahydrate or platinum catalysts containing carbene ligands, as described in patent US 3,775,452, are preferred.

[0058] Preferably, component D is a solution of a platinum complex in a vinyl terminated polydimethylsiloxane.

[0059] According to one embodiment of the present invention, the solvent E is 6 ~C 16 Aliphatic hydrocarbons, polydimethylsiloxanes containing trimethylsilyl end groups and with a viscosity of 0.65 mPa·s to 5 mPa·s at 25°C, cyclic polydimethylsiloxanes, (3-octyl)heptamethyltrisiloxane, toluene, xylene, C 1~C 8 Alkyl esters, C 2 ~C 4 The carboxylic acid is selected from the group consisting of carboxylic acids and mixtures thereof.

[0060] In particular, solvent E is at least one solvent. Solvent E is at least one solvent approved for medical use. For example, it is selected from toluene, xylene, heptane, ethyl acetate, more preferably ethyl acetate for medical use.

[0061] The amount of the solvent is 20% by weight to 70% by weight, preferably 30% by weight to 60% by weight, based on the total weight of the composition.

[0062] A hydrosilylation inhibitor F may be used in the composition.

[0063] Examples of inhibitors of hydrosilylation reactions useful according to the present invention include α-acetylenic alcohols, α,α'-acetylenic diesters, enyne conjugate compounds, α-acetylenic ketones, acrylonitrile, maleates, fumarates and mixtures thereof. These compounds can act as hydrosilylation inhibitors and are well known to those skilled in the art. They can be used alone or in mixtures.

[0064] The α-acetylenic alcohol type inhibitor is selected from the compounds of formula (F1) [ka] Where: ·R 8 The group is an alkyl group, a cycloalkyl group, a (cycloalkyl)alkyl group, C 6 ~C 10 Aryl group or C 7 ~C 18 represents an arylalkyl group, ·R 9 The group is a hydrogen atom, an alkyl group, a cycloalkyl group, a (cycloalkyl)alkyl group, C 6 ~C 10Aryl group or C 7 ~C 18 represents an arylalkyl group, Or R 8 and R 9 together with the carbon atoms to which they are attached form a 5-, 6-, 7- or 8-membered aliphatic ring which may be substituted one or more times.

[0065] According to formula (F1), The term "alkyl" is understood to mean a saturated hydrocarbon chain containing 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms. The alkyl group may be selected from the group consisting of methyl, ethyl, isopropyl, n-propyl, tert-butyl, isobutyl, n-butyl, n-pentyl, isoamyl and 1,1-dimethylpropyl. The term "cycloalkyl" is understood according to the present invention to mean a saturated monocyclic or polycyclic, preferably monocyclic or bicyclic, hydrocarbon radical containing 3 to 20 carbon atoms, preferably 5 to 8 carbon atoms. If the cycloalkyl radical is polycyclic, the ring nuclei can be linked to each other via covalent bonds and / or via spiran atoms and / or can be fused to each other. The cycloalkyl radical can be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantane and norbornane. The term "(cycloalkyl)alkyl" is understood according to the invention to mean a cycloalkyl group, as defined above, linked to an alkyl group, as also defined above. The term "aryl" is understood according to the invention to mean an aromatic hydrocarbon radical, which contains 6 to 10 carbon atoms and is monocyclic or polycyclic. The aryl radical may be selected from the group consisting of phenyl, naphthyl and anthracenyl. The term "arylalkyl" is understood according to the invention to mean an aryl group, as defined above, linked to an alkyl group, as also defined above.

[0066] According to a preferred embodiment, in formula (F1), R 8 and R 9 Together with the carbon atoms to which they are attached, R constitutes an unsaturated 5-, 6-, 7- or 8-membered aliphatic ring. 8 and R 9 are the same or different and are each independently a monovalent C 1 ~ 12 , preferably C 1 ~C 6 represents an alkyl group represented by the formula:

[0067] The α-acetylenic alcohol inhibitors useful according to the invention can be selected from the group consisting of the following compounds: 1-ethynyl-1-cyclopentanol; 1-ethynyl-1-cyclohexanol (also known as ECH); 1-ethynyl-1-cycloheptanol; 1-ethynyl-1-cyclooctanol; 3-methyl-1-butyn-3-ol (also known as MBT); 3-methyl-1-pentyn-3-ol; 3-methyl-1-hexyn-3-ol; 3-methyl-1-heptyn-3-ol; 3-methyl-1-octyn-3-ol; 3-methyl-1-nonyn-3-ol; 3-methyl-1-decyn-3-ol; 3-methyl-1-dodecyn-3-ol; 3-methyl-1-pentadecyn-3-ol; 3-ethyl-1-penty 1-Heptyn-3-ol; 3-Ethyl-1-hexyn-3-ol; 3-Ethyl-1-heptyn-3-ol; 3,5-Dimethyl-1-hexyn-3-ol; 3-Isobutyl-5-methyl-1-hexyn-3-ol; 3,4,4-Trimethyl-1-pentyn-3-ol, 3-Ethyl-5-methyl-1-heptyn-3-ol; 3,6-Diethyl-1-nonyn-3-ol; 3,7,11-Trimethyl-1-dodecyn-3-ol (also known as TMDDO); 1,1,-Diphenyl-2-propyn-1-ol; 3-Butyn-2-ol; 1-Pentyn-3-ol; 1-Heptyn-3-ol; 1-Heptyn-3-ol; 5-Methyl-1-hexyn-3-ol; 4-Ethyl-1-octyn-3-ol and 9-Ethynyl-9-fluorenol.

[0068] The α,α'-acetylene diester type inhibitor is selected from the compounds of formula (F2) [ka] Here, R 10 and R 11 The groups are the same or different and are independently an alkyl group, a cycloalkyl group, a (cycloalkyl)alkyl group, C 6 ~C 10 Aryl group, C 7 ~C 18 It represents an arylalkyl group or a silyl group.

[0069] The term "silyl" means, according to the present invention, a group of the formula -SiR 3 where each R symbol independently represents an alkyl group containing 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms. The silyl group can be, for example, a trimethylsilyl group.

[0070] According to a particular embodiment, in formula (F2), R 10 and R 11 The groups are the same or different and are independently 1 ~C 12 , preferably C 1 ~C 6 represents an alkyl group or a trimethylsilyl group. The α,α'-acetylene diester inhibitors useful according to the present invention can be selected from the group consisting of the following compounds: dimethylacetylene dicarboxylate (DMAD), diethylacetylene dicarboxylate, di(tert-butyl)acetylene dicarboxylate and bis(trimethylsilyl)acetylene dicarboxylate.

[0071] The inhibitor of the enyne conjugate compound type can be selected from the compounds of formula (F3) [ka] Where: ·R12 , R 13 and R 14 The groups are each independently a hydrogen atom, an alkyl group, a cycloalkyl group, a (cycloalkyl)alkyl group, 6 ~C 10 Aryl group, or C 7 ~C 18 represents an arylalkyl group, Or R 12 , R 13 and R 14 At least two of the groups, together with the carbon atom or carbon atoms to which they are attached, form a 5-, 6-, 7- or 8-membered aliphatic ring which may be substituted one or more times.

[0072] According to a particular embodiment, R 12 , R 13 and R 14 The groups are each independently a hydrogen atom, 1 ~C 12 , preferably C 1 ~C 6 Alkyl group or C 6 ~C 10 Represents an aryl group. The inhibitors that are useful enyne conjugate compounds according to the invention can be selected from the group consisting of: 3-methyl-3-penten-1-yne; 3-methyl-3-hexen-1-yne; 2,5-dimethyl-3-hexen-1-yne; 3-ethyl-3-buten-1-yne; and 3-phenyl-3-buten-1-yne. According to another particular embodiment, R 12 , R 13 and R 14 Two groups selected from the group are taken together with one or more carbon atoms to which they are attached to form an unsaturated 5-, 6-, 7- or 8-membered aliphatic ring, and the remaining third group is a hydrogen atom or C 1 ~C 12 , preferably C 1 ~C 6 represents an alkyl group. The inhibitor, which is an enyne conjugate compound useful according to the present invention, can be 1-ethynyl-1-cyclohexene.

[0073] The α-acetylene ketone type inhibitor may be selected from the compounds of formula (F4) [ka] Here, R 15 is an alkyl group, a cycloalkyl group, a (cycloalkyl)alkyl group, C 6 ~C 10 Aryl group or C 7 ~C 18 It represents an arylalkyl group, where the alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl or arylalkyl group can be optionally substituted one or more times by chlorine, bromine or iodine atoms.

[0074] According to a preferred embodiment, R 15 is a monovalent C which may be substituted one or more times by a chlorine or bromine atom 1 ~ 12 , preferably C 1 ~C 6 Alkyl group, or cycloalkyl group, or C 6 ~C 10 Represents an aryl group. The α-acetylene ketone inhibitors useful according to the present invention can be selected from the group consisting of the following compounds: 1-octyn-3-one, 8-chloro-1-octyn-3-one; 8-bromo-1-octyn-3-one; 4,4-dimethyl-1-octyn-3-one; 7-chloro-1-heptyn-3-one; 1-hexyn-3-one; 1-pentyn-3-one; 4-methyl-1-pentyn-3-one; 4,4-dimethyl-1-pentyn-3-one; 1-cyclohexyl-1-propyn-3-one; benzoacetylene and (o-chlorobenzoyl)acetylene.

[0075] The acrylonitrile type inhibitor may be selected from the compounds of formula (F5) [ka] Here, R 16 and R 17are each independently a hydrogen atom, a chlorine atom, a bromine atom or an iodine atom, an alkyl group, a cycloalkyl group, a (cycloalkyl)alkyl group, C 6 ~C 10 Aryl group or C 7 ~C 18 It represents an arylalkyl group, where the alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl or arylalkyl group can be optionally substituted one or more times by chlorine, bromine or iodine atoms.

[0076] Acrylonitrile inhibitors useful according to the present invention may be selected from the group consisting of the following compounds: acrylonitrile; methacrylonitrile; 2-chloroacrylonitrile; crotononitrile and cinnamonitrile.

[0077] The maleate or fumarate type inhibitor may be selected from the compounds of formula (F6) and (F7) below: [ka] Here, R 18 and R 19 are the same or different and are independently an alkyl or alkenyl group, a cycloalkyl group, a (cycloalkyl)alkyl group, C 6 ~C 10 Aryl group, or C 7 ~C 18 It represents an arylalkyl group, and the aforementioned alkyl group, alkenyl group, cycloalkyl group, (cycloalkyl)alkyl group, aryl group and arylalkyl group can be substituted by an alkoxy group.

[0078] The term "alkenyl" is understood according to the present invention to mean a saturated hydrocarbon chain containing 2 to 6 carbon atoms and containing at least one double unsaturation. Preferably, the alkenyl group is selected from the group consisting of vinyl and allyl. The term "alkoxy" is understood according to formulae (F6) and (F7) to mean an alkyl group as defined above attached to an oxygen atom. The alkoxy group can be selected from the group consisting of methoxy, ethoxy, propoxy and butoxy.

[0079] According to a particular embodiment, R 18 and R 19 are the same or different, and independently of each other, C 1 ~C 6 C optionally substituted by an alkoxy group 1 ~ 12 , preferably C 1 ~C 6 represents an alkyl group or an alkenyl group.

[0080] Maleate or fumarate inhibitors useful according to the present invention may be selected from the group consisting of diethyl fumarate, diethyl maleate, diallyl fumarate, diallyl maleate and bis(methoxyisopropyl) maleate.

[0081] These inhibitors can be added in an amount of 1 ppm to 50,000 ppm by weight, particularly 10 ppm to 10,000 ppm, preferably 20 ppm to 2000 ppm, and more preferably 800 ppm to 2000 ppm by weight, based on the weight of the total silicone composition.

[0082] The medical silicone pressure sensitive adhesive composition according to the invention can be applied to a variety of substrates suitable for medical use. The substrates can be supports of very diverse nature, depending on the field of application.

[0083] According to a preferred embodiment, the substrate is a woven, nonwoven or knitted textile product or a plastic film. The term "nonwoven" is understood to mean any structure of fibrous material, such as fibers, continuous filaments or chopped threads, whatever its nature or origin, formed into a network and bound in any way, except for intertwining of threads. Nonwovens are products that have the appearance of a textile product, are porous, are mainly composed of fibers and are produced by processes other than spinning, weaving, knitting or knotting.

[0084] According to another preferred embodiment, the substrate is made of plastic. A wide variety of plastics may be suitable for use as a substrate according to the invention. Examples include polyvinyl chloride, polypropylene, regenerated cellulose, polyethylene terephthalate (PET) and polyurethane, in particular meltblown polyurethane. The substrate may be a perforated flexible polyurethane film or a continuous flexible polyurethane film. The flexible polyurethane film may be produced from meltblown polyurethane. When the substrate is a flexible polyurethane film, its thickness is generally 5 μm to 600 μm, preferably 5 μm to 250 μm, more preferably 10 μm to 100 μm.

[0085] Alternatively, the substrate may be selected from paper, nonwovens and elastic fabrics.

[0086] According to a preferred embodiment, the substrate may be selected from paper, nonwoven fabric, elastic fabric or plastic film, preferably a film of a plastic selected from the group consisting of polyvinyl chloride, polypropylene, regenerated cellulose, polyethylene terephthalate (PET) and polyurethane.

[0087] Those skilled in the art can adjust the medical silicone pressure-sensitive adhesive composition according to the end use. In general, the medical silicone pressure-sensitive adhesive composition according to the present invention can have a dynamic viscosity at 25°C of 500 mPa·s to 5000 mPa·s, preferably 800 mPa·s to 3000 mPa·s, more preferably 1000 mPa·s to 2500 mPa·s.

[0088] The medical silicone pressure-sensitive adhesive composition according to the invention can be applied or coated on various substrates by any technique well known to those skilled in the art. Techniques for depositing the medical silicone pressure-sensitive adhesive composition according to the invention can include, for example, coating techniques carried out by knife, especially knife over roll, floating knife and knife over carpet, or by padding, i.e. squeezing between two rolls, or by licking roll, rotary machine, reverse roll or transfer, or by spraying. Other coating techniques can include curtain coating techniques. Curtain coating is a method of applying a coating liquid to an article or support. Curtain coating is characterized by the formation of a free-falling curtain of coating liquid that, under the influence of gravity, falls from the lip of a hopper and advances the curtain to contact the article for the formation of a coating. This technique is widely used in the field of preparation of multilayer photosensitive silver supports (see, for example, patents US 3,508,947, US 3,508,947 and EP 537086).

[0089] The medical silicone pressure-sensitive adhesive composition coated on the substrate is then crosslinked at a temperature of, for example, 100°C to 160°C, preferably 120°C to 150°C.

[0090] In this way, a substrate coated with silicone pressure sensitive adhesive G is obtained by crosslinking the silicone pressure sensitive adhesive composition according to the invention.

[0091] Other advantages and features of the invention will become apparent on reading the following examples, given by way of illustration and not in any way limiting. EXAMPLES

[0092] Probe Tack Test : The tack test is performed by cutting the cured PSA lamination into 2.5 cm (length) x 2.5 cm (width) strips, removing the release liner from the PSA layer, and performing the tack test according to ASTM D2979 with a PT1000 probe tack tester manufactured by Cheminstrument Co. Ltd. The atmospheric conditions are 23°C and 50% RH.

[0093] Peel Adhesion : Peel adhesion test is carried out by cutting the cured PSA lamination into strips of 2.5cm (length) x 2.5cm (width), removing the release liner from the PSA layer, adhering the PSA layer to a card paper of size 15cm x 5cm, and laminating them with a 2kg rubber roller for two cycles. Then, the peel test is carried out on a PA1000-180 peel tester manufactured by Cheminstrument Co.Ltd according to FINAT FTM1. The atmospheric conditions are 23°C and 50% RH.

[0094] The raw materials used in the examples are shown below. Organopolysiloxane A: Vinyl-terminated polydimethylsiloxane gum M Vi D x M Vi , Mw=560,000g / mol, vinyl content=0.015wt%, consistency=800mm / 10 Organopolysiloxane resin B:M x Q y Q (OH) z Resin, Mw=5,500g / mol, x / (y+z)=0.9, OH=1.0% by weight Extender CE: Hydrogen-terminated polydimethylsiloxane oil M H D y M H, viscosity=8.0mPa·s, Si-H content=5.51wt% Catalyst D: Pt content = 0.2 wt%, dissolved in vinyl-terminated polydimethylsiloxane with a viscosity of 350 mPa·s Solvent E: Ethyl acetate

[0095] Examples 1-5 All ingredients were mixed homogeneously in the amounts shown in the table below. The obtained composition was coated onto a PET film using a blade (60 to 90 g / m 2 ), then placed in a 120°C oven for 30 minutes.

[0096] [Table 1]

[0097] The composition according to the invention (Example 3) provides an adhesive with very good properties after curing, which can be advantageously used as a medical PSA.Below the claimed molar ratio RHAlk (Examples 1 and 2), the composition does not show a cohesive network.Beyond the claimed molar ratio RHAlk (Examples 4 and 5), the cured composition loses its release and appears to be more elastomer-like.

Claims

1. A medical silicone pressure-sensitive adhesive composition, comprising: At least two C atoms per molecule, each bonded to a silicon atom 2 ~C 6 at least one organopolysiloxane A containing alkenyl groups, the organopolysiloxane A being an organopolysiloxane gum; at least one organopolysiloxane resin B containing one or more OH groups bonded to silicon atoms; at least one organopolysiloxane extender CE having exactly two terminal hydrogen atoms bonded to a silicon atom; optionally at least one organopolysiloxane crosslinker XL having at least three hydrogen atoms bonded to silicon atoms; at least one hydrosilylation catalyst D; at least one solvent E; optionally at least one hydrosilylation inhibitor F; Including, The organopolysiloxane A, the organopolysiloxane extender CE, and the organopolysiloxane crosslinker XL have a molar ratio RHAlk=tH / tAlk of 2 to 5, and a ratio nH XL / nH CE is selected to be less than 0.10, where tH = the number of moles of hydrogen atoms directly bonded to silicon atoms of the organopolysiloxane extender CE and the organopolysiloxane crosslinker XL; tAlk=the number of moles of alkenyl directly bonded to silicon atoms of the organopolysiloxane A; nH XL = the number of moles of hydrogen atoms directly bonded to silicon atoms in the organopolysiloxane crosslinker XL, nH CE = the number of moles of hydrogen atoms directly bonded to silicon atoms of the organopolysiloxane extender CE, the organopolysiloxane A is used in an amount of 15% to 45% by weight, based on the total amount of components A+B+XL+CE; the organopolysiloxane resin B is used in an amount of 25% by weight to 80% by weight, based on the total amount of components A+B+XL+CE; A medical silicone pressure-sensitive adhesive composition, wherein the organopolysiloxane A has an alkenyl content of 0.001% to 0.5% by weight based on the total amount of the organopolysiloxane A.

2. 2. The medical silicone pressure-sensitive adhesive composition of claim 1, wherein the molar ratio RHAlk is 2.5 to 4.

3. Said ratio nH XL / nH CE 2. The medical silicone pressure-sensitive adhesive composition of claim 1, wherein is precisely less than 0.

10.

4. 10. The medical silicone pressure-sensitive adhesive composition of claim 1, wherein the medical silicone pressure-sensitive adhesive composition is free or substantially free of organohydrogensiloxane crosslinker XL.

5. 2. The medical silicone pressure-sensitive adhesive composition of claim 1, wherein the organopolysiloxane A is selected from dimethylvinyl-terminated polydimethylsiloxanes, dimethylvinyl-terminated polydimethylmethylvinylsiloxanes, and trimethyl-terminated polydimethylmethylvinylsiloxanes.

6. 2. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein said organopolysiloxane A is an organopolysiloxane gum having a consistency at 25° C. of 200 mm / 10 to 2000 mm / 10.

7. 2. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the organopolysiloxane A is used in an amount of 20% to 40% by weight, based on the total amount of components A+B+XL+CE.

8. The organopolysiloxane resin B containing a hydroxyl group is a) a compound of the formula: M=R 3 R 4 R 5 SiO 1 / 2 , and Q (OH) =(OH)SiO 3 / 2 M and Q (OH) Contains siloxy units, Optionally, siloxy units Q = SiO 4 / 2 is a copolymer in which (OH) Hydroxylated silicone resins of the type b) a compound of the formula: M=R 3 R 4 R 5 SiO 1 / 2 、 D Vi = (Vi) (R 3 ) SiO 2 / 2 and Q (OH) =(OH)SiO 3 / 2 M, D Vi and Q (OH) Contains siloxy units, Optionally, siloxy units Q = SiO 4 / 2 MD is a copolymer in which Vi Q (OH) Hydroxylated silicone resins of the type c) a compound of the formula: M=R 3 R 4 R 5 SiO 1 / 2 、 M Vi = (Vi) (R 3 ) (R 4 ) SiO 2 / 2 and Q (OH) =(OH)SiO 3 / 2 M, M Vi and Q (OH) Contains siloxy units, Optionally, siloxy units Q = SiO 4 / 2 is a copolymer in which Vi Q (OH) Hydroxylated silicone resins of the type d) a compound of the formula: M=R 3 R 4 R 5 SiO 1 / 2 、 D=R 3 R 4 SiO 2 / 2 、 T (OH) =(OH)R 3 SiO 2 / 2 、 T=R 3 SiO 3 / 2 M, D, T (OH) and MDT, a copolymer containing T siloxy units. (OH) T-type hydroxylated silicone resins, and e) a compound of the formula: D=R 3 R 4 SiO 2 / 2 、 T (OH) =(OH)R 3 SiO 2 / 2 、 T=R 3 SiO 3 / 2 D, T (OH) and T siloxy units, DT (OH) T-type hydroxylated silicone resin is selected from the group consisting of where the symbol Vi is a vinyl group and the symbol R 3 , R 4 and R 5 But independently of each other, a linear or branched alkyl group having 1 to 8 carbon atoms and optionally substituted with one or more halogen atoms; an aryl or alkylaryl group having 6 to 14 carbon atoms; 2. The medical silicone pressure-sensitive adhesive composition of claim 1, wherein the adhesive is selected from the group consisting of:

9. 2. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the organopolysiloxane resin B is used in an amount of 40% to 60% by weight, based on the total amount of components A, B, XL, and CE.

10. The organopolysiloxane extender CE is of the formula M H D X M H where: M H =Formula: (H) (CH 3 ) 2 SiO 1 / 2 is a siloxyl unit of D=Formula: (CH 3 ) 2 SiO 2 / 2 is a siloxyl unit of 2. The medical silicone pressure-sensitive adhesive composition of claim 1, wherein x is an integer from 1 to 200.

11. The solvent E is C 6 ~C 16 Aliphatic hydrocarbons, polydimethylsiloxanes containing trimethylsilyl end groups and having a viscosity of 0.65 mPa·s to 5 mPa·s at 25°C, cyclic polydimethylsiloxanes, (3-octyl)heptamethyltrisiloxane, toluene, xylene, C 1 ~C 8 Alkyl esters, C 2 ~C 4 10. The medical silicone pressure sensitive adhesive composition of claim 1, wherein the carboxylic acid is selected from the group consisting of carboxylic acids and mixtures thereof.

12. 2. The medical silicone pressure-sensitive adhesive composition of claim 1, wherein the amount of solvent E is 20% to 70% by weight, based on the total weight of the medical silicone pressure-sensitive adhesive composition.

13. A method for producing a skin-adhesive article, comprising the steps of coating at least one of two surfaces of a substrate continuously or discontinuously with the medical silicone pressure-sensitive adhesive composition of any one of claims 1 to 12, and crosslinking the medical silicone pressure-sensitive adhesive composition to form a silicone pressure-sensitive adhesive G.

14. The method of claim 13 , wherein the substrate is selected from paper, a nonwoven fabric, an elastic fabric, or a plastic film.

15. A skin-adhesive article comprising a substrate, at least one of two surfaces of which is continuously or discontinuously coated with a silicone pressure-sensitive adhesive G obtained by crosslinking the medical silicone pressure-sensitive adhesive composition according to any one of claims 1 to 12.

Images